ProCE Banner Activity

GRIFFIN Maintenance Phase Update: Daratumumab + VRd → Dara-R vs VRd → R Alone for ASCT-Eligible Patients With Newly Diagnosed MM

Slideset Download
Conference Coverage
Data from the maintenance phase of GRIFFIN trial with D-VRd + DR maintenance led to significant improvement in sCR and depth of response vs VRd + R maintenance.

Released: December 09, 2020

Expiration: December 08, 2021

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology